Even a drug that modestly adds to the efficacy of existing cholesterol drugs can be a big seller.

FORBES: Magazine Article

What would make payers and patients want to pay such exorbitant prices for cholesterol lowering in the face of generic statins with their track record of safety and efficacy?

FORBES: Will Sanofi & Regeneron Ride ODYSSEY Into Riches?